Antimicrobial resistance (AMR) is a serious problem with multidrug-resistant (MDR) (resistant to at least 2 classes of agents) strains of fungi and bacteria that affect medical progress in many regions of the world [1] [2] [3] [4] . Collecting AMR surveillance data is essential to define the scope of the resistance problem and to develop interventions that improve the appropriate use of antimicrobial agents and decrease resistance selection pressure [5] [6] [7] . Another important effort is to understand the mechanisms of resistance whereby microorganisms avoid the effects of antimicrobial agents and to use this information to develop new agents, or modify older agents, that retain potent activity against the key target pathogens [1, 8, 9] . AMR reduces the potential efficacy of agents, including antifungal agents such as the azole and echinocandin classes, that are commonly used to treat or prevent serious fungal infections in target patient populations [6, 10, 11] .
The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12] ; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs. A higher prevalence of IFI has been observed in recent decades due to the increasing immunocompromised patient population, including individuals living with HIV, organ transplant recipients, and cancer patients [13, 14] . Increasing populations of the elderly, neonates, and patients requiring invasive therapies also contribute to higher IFI rates [5, 6, 15] .
Candidemia and other forms of invasive candidiasis (IC; including infections of normally sterile body fluids, deep tissues, and organs) are the most important of the invasive mycoses [1, [16] [17] [18] . Although Candida isolates displaying resistance to clinically available antifungal agents are still uncommon, these organisms are increasingly reported worldwide [19, 20] . Thus, continuously monitoring antifungal susceptibility patterns and resistance mechanisms to clinically used antifungal agents is increasingly important.
The epidemiology of candidemia and IC (collectively referred to as IC for the purposes of this discussion) has been described in numerous single-center, sentinel, and population-based surveys conducted worldwide [5-7, 21, 22] . However, the dynamic nature of IC trends in the United States and elsewhere suggests that this issue still merits considerable monitoring [6, 12, [23] [24] [25] [26] . The SENTRY Antifungal Surveillance Program is a global program that has been ongoing for 20 years (1997-2016) and collects consecutive invasive Candida isolates from medical centers located in North America (NA), Europe (EUR), Latin America (LATAM), and the Asia-Pacific (APAC) region during each calendar year. Candida spp. isolates are evaluated for susceptibility against various antifungal agents used clinically to treat and prevent IC [27] . Applying modern methods for species identification, testing antifungal susceptibility, and characterizing antifungal resistance mechanisms provides a level of standardization and clarity that makes these observations useful in the ongoing fight against antifungal resistance [1, 5, 6, 9, [28] [29] [30] [31] [32] [33] .
We have reported broad geographic trends in the isolation of various Candida species from clinical specimens and the accompanying rates of antifungal resistance in the United States and internationally in numerous SENTRY Program publications in the peer-reviewed literature spanning 1997 through 2016 [9, 29, 34] . We now summarize the geographic and temporal variations in the frequency of Candida species that cause IC and associated antifungal resistance profiles using the extensive SENTRY Antifungal Surveillance Program database, which includes results for 20 788 invasive isolates of Candida species from 135 medical centers in 39 nations. In this analysis, we emphasize regional epidemiological data and their impact on empiric antifungal therapy.
METHODS

Study Design
The SENTRY Program was established to monitor the predominant pathogens and antimicrobial resistance patterns of nosocomial and community-onset infections via a broad network of sentinel medical centers distributed by geographic location and size. Participating medical centers submit organisms each calendar year through a prevalence-based approach across several infection types. The current study design collects clinical isolates under the following objectives: bloodstream, skin and skin structure, respiratory, urinary tract, intra-abdominal, and invasive fungal infections, as well as pathogens from patients hospitalized with pneumonia (described at https://www.jmilabs. com/sentry-surveillance-program/). Participating institutions contributing Candida spp. isolates have included 135 medical centers in 39 countries: 41 in the United States, 4 in Canada, 14 in LATAM, 25 in APAC, and 51 in EUR.
Each participating medical center contributed findings (organism identification, isolation date, and site) on consecutive IC episodes in each calendar month. Additional demographic and epidemiological data were recorded on a data form forwarded with each isolate. All isolates were saved and sent weekly to either the University of Iowa (Iowa City, IA; 1997-2005) or JMI Laboratories (North Liberty, IA; 2006-2016) for storage and for further characterization by reference identification and susceptibility testing methods.
Organism Identification
Isolates (1 per patient infection episode) were identified at participating institutions using methods routinely employed at the submitting laboratory, including the use of the Vitek, MicroScan, API, and AuxaColor systems supplemented by classical methods for yeast identification [35] . Isolates were submitted to the 2 monitoring laboratories, where identification was confirmed by morphological, biochemical, and molecular methods [9, 23, 30, 35] . All isolates were subcultured to CHROMagar (Becton, Dickinson and Company, Sparks, MD) to differentiate Candida albicans/Candida dubliniensis, Candida tropicalis, and Candida krusei. Isolates collected and tested from 2006 to 2009 showing morphology discrepant with the identification submitted by the participating laboratory had identification confirmed using the Vitek yeast identification system (bioMerieux, Hazelwood, MO). Any further discrepancies were resolved by molecular or proteomic methods, as described below. Biochemical and physiological tests such as growth at 45°C (C. albicans, C. dubliniensis) and assimilation of trehalose (Candida glabrata) were applied centrally to isolates submitted from 2010 through 2016. C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei isolates that were not identified by these methods during 2010 and 2011, and all uncommon species were identified using sequence-based methods for internal transcribed spacer region and/or 28S ribosomal subunits, according to protocols previously described [9, 30] . From 2012 to 2016, isolate identification was confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (Bruker, Billerica, MA). Isolates that were not identified by either phenotypic or proteomic methods were identified using sequence-based methods, as previously described [30, 36, 37] .
Susceptibility Testing
All isolates were tested by broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) methods, as outlined in documents M27-A3 and M27-S4 [38, 39] . The systemically active antifungal agents tested were anidulafungin, caspofungin, micafungin, fluconazole, and voriconazole. This report focuses primarily on resistance to fluconazole and the echinocandins. The results for voriconazole will only be used when discussing cross-resistance between azoles and echinocandins. The range of antifungal agent concentrations tested was 0.008-16 mg/L for the echinocandins and voriconazole and 0.12-128 mg/L for fluconazole. Minimum inhibitory concentration (MIC) results for all tested agents were determined visually after 24 hours of incubation at 35°C as the lowest concentration of agent that resulted in ≥50% inhibition of growth relative to the growth control. CLSI clinical breakpoints (CBPs) were applied for the 5 most "common" species of Candida (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei), for which echinocandins, fluconazole, and voriconazole are used in treatment. Epidemiological cutoff values (ECVs) were applied when available for the other species tested [37, 38, 40] . Recognizing that CBPs for fluconazole and the echinocandins have changed over the last 20 years, we have applied only the most contemporary CBPs and ECVs to the entire Candida spp. collection [38] [39] [40] . Quality control was performed as recommended in CLSI M27-A3 using C. krusei ATCC 6258 and C. parapsilosis ATCC 22019. All results were within established ranges.
Screening for FKS HS Mutations
Candida spp. isolates with MIC values higher than the CBP for the echinocandin compounds were submitted to polymerase chain reaction (PCR) and sequencing for hot spots (HS) of the FKS genes encoding the 1,3 β-D-glucan synthase (GS) subunits. PCR amplification was completed using previously described oligonucleotides for the FKS1 and FKS2 HS 1 and 2 [41, 42] .
RESULTS
Organism Collection
A total of 20 788 invasive isolates of Candida spp. [43] , it is notable that a marked decrease in central line-associated BSIs has been identified in US hospitals over this time period [44, 45] . The frequency of C. tropicalis and C. krusei as IC isolates was more stable over time, with IC ranges of 8.3%-10.7% and 2.1%-3.2%, respectively. Notably, the overall frequency of C. krusei as a cause of IC remained low at 2.8% (range, 2.1%-3.2%) for the 20-year period despite continued utilization of fluconazole in most medical centers [46] [47] [48] [49] . In aggregate, the frequency of miscellaneous species of Candida (non-top-5 species) showed a steady increase from 2.7% of infections in 1997-2001 to 8.5% in 2015-2016. The frequencies of IC due to the 5 most common species of Candida in the 4 geographic areas participating in the SENTRY Program are shown in Table 2 . C. albicans was most common in EUR (52.5%) and least common in NA (United States and Canada; 42.7%), whereas C. glabrata was most common in NA (24.3%) and least common in LATAM (7.1%). C. parapsilosis and C. tropicalis were more common than C. glabrata in LATAM (24.3% and 17.0% vs 7.1%, respectively). C. tropicalis was also a frequent cause of IC in the APAC region (14.1%). C. krusei was more common in NA (2.9%) and EUR (3.0%), and other miscellaneous species of Candida were common in APAC (7.3%) and NA (7.3%) (data not shown).
Trends in Fluconazole Resistance in Relation to Time, Geographic Area, and Species of Candida in IC
Fluconazole Resistance Variation by Species and by Year
The fluconazole resistance profile of the 4 most common species of Candida ranged from 0.3% (C. albicans) to 8.1% resistant (C. glabrata) using the most recent CBPs (Table 3) : C. krusei is not listed as it is considered intrinsically (100.0%) resistant to fluconazole [38, 39, 50] . The low fluconazole resistance rate among C. albicans isolates is consistent with previous reports [51] and showed very little change from 0.2% in 1997-2001 to 0.1% in 2015-2016. Resistance to fluconazole showed an increase from 1997 through 2014 for C. glabrata (8.6% to 10.1%) and C. tropicalis (2.5% to 4.9%), with a slight decline for both species in 2015-2016, possibly due to increased use of echinocandins over fluconazole in those years [26, 44, 46, 48] . Given past recommendations to use fluconazole as firstline therapy for C. parapsilosis infections [52] , it is notable that fluconazole resistance increased over time for this species (Table 3) . Table 4 presents the resistance rates for fluconazole tested against the 4 most common species of Candida stratified by geographic region from 2006 through 2016. Just as geographic variation was observed in the frequency of isolation of these species (Table 2) , variation in the frequency of fluconazole resistance was noted as well. Although fluconazole was highly active against C. albicans in all geographic regions, slightly higher rates of resistance were seen in isolates from NA (0.4%) compared with those from the other 3 regions (range, 0.1%-0.2%). The overall increase in fluconazole resistance for C. glabrata in this survey was reflected in high rates of resistance in isolates from APAC (6.8%) and NA (10.6%). Not only was C. glabrata an uncommon cause of IC in LATAM, it was also less resistant to this agent (2.6%) compared with the other monitored regions.
Fluconazole Resistance by Geographic Area and Species
C. parapsilosis isolates from EUR (4.6% resistance) and LATAM (4.3% resistance) showed the highest rates of resistance to fluconazole, whereas only 0.6% of C. parapsilosis isolates from the APAC region were resistant.
Resistance to fluconazole was detected in 9.2% of C. tropicalis isolates from the APAC region and was considerably less frequent in the other 3 regions (range, 1.1%-2.9%) ( Table 4 ). These findings build upon our previous global surveillance data that indicate that the highest rates of fluconazole resistance among C. tropicalis BSI isolates were observed among isolates from the APAC region [53] .
Previously, we examined the fluconazole susceptibilities of BSI isolates of C. glabrata from US centers participating in the SENTRY Program and grouped the isolates by geographic location within the United States from 1992 to 2007 [54] . In the present study, we build upon this experience and report the fluconazole susceptibilities of an additional 5366 C. glabrata isolates collected from sentinel surveillance sites throughout the United States from 2008 through 2016 and stratify the results by US region (Table 5) . Overall, C. glabrata accounted for 25% of all US IC isolates, ranging from 22% in the Northeast to 27% in the West (Table 5) . Compared with 1992-2001 [29] and 2001-2007 surveys [54] , the proportion of IC isolates that were C. glabrata increased in all 4 regions.
Fluconazole susceptibilities of C. glabrata isolates also varied by US region ( Table 5 (Table 5) . Studies have shown that the prevalence of C. glabrata as a cause of BSI is potentially related to many disparate factors in addition to fluconazole exposure, including geography, patient age, and other characteristics of the patient population studied [6, 16, 24, 26, 55, 56] . Few surveys have examined the frequency of isolation and resistance to fluconazole among C. glabrata isolates according to patient age group [5, 17, 23-25, 33, 54, 56, 57] . Table 6 shows the frequency of isolation and fluconazole resistance among C. glabrata isolates stratified according to patient age group for all geographic regions from 2006 through 2016. Previously, we demonstrated that although the proportion of BSI isolates of Candida that were C. glabrata increased with patient age in the United States, the rate of fluconazole resistance declined [54] . An identical trend was observed in the present geographically diverse study. The frequency of C. glabrata causing IC increased steadily from 6.4% in the ≤1-19-year age group to 22.3% in the ≥70-year age group, but only 4.0% of isolates in the older age group were resistant to fluconazole. The highest resistance rates were in the 20-49-year (11.8% resistant) and 50-69-year (9.8% resistant) age groups.
Consistent with previous observations [54-56, 58, 59 ], very few infections due to C. glabrata were seen in the pediatric and adolescent age groups (≤19 years) ( Table 6 ). Only 134 C. glabrata IC isolates from patients who were ≤19 years of age were submitted to the SENTRY Program. In contrast to the percentage of resistant isolates observed in 2008-2009 for isolates from this age group (0.0%) [56] , 8 .2% of the current isolates were resistant to fluconazole. This increased resistance may reflect the increased use of fluconazole prophylaxis and treatment in these groups of younger patients [16, 47, 60] .
Cross-Resistance Between Fluconazole and Voriconazole
Voriconazole has been demonstrated to have useful clinical activity in treating mucosal and invasive forms of candidiasis [61, 62] . The clinical indication for using voriconazole in IC has been primarily for oral step-down therapy in patients with infections due to C. krusei and fluconazole-resistant, voriconazole-susceptible C. glabrata [50] . We have shown variable cross-resistance between fluconazole and voriconazole when tested against the common species of Candida causing IC [53, 63, 64] . These findings were confirmed in the present survey, where cross-resistance between fluconazole and voriconazole was common in fluconazole-resistant C. albicans (35.0% susceptible to voriconazole) and C. parapsilosis (32.7% susceptible to voriconazole) strains and virtually complete for fluconazole-resistant strains of C. glabrata (0.0% susceptible [MIC, ≤0.5 mg/L] to voriconazole) and C. tropicalis (3.6% susceptible to voriconazole) (data not shown). Conversely, voriconazole was reliably active against C. krusei (95.0% susceptible) isolates, all of which were resistant to fluconazole (data not shown). Aside from C. krusei, the other species of Candida usually encountered in IC are not optimal targets for voriconazole when fluconazole resistance is observed [50] .
Trends in Echinocandin Resistance in Relation to Time, Geographic Area, and Species of Candida in IC
Variation in Echinocandin Resistance by Species and Surveillance Year
The echinocandin class of antifungal agents acts by inhibition of the synthesis of 1,3-β-D-glucan in the fungal cell wall [65] . All 3 available echinocandins-anidulafungin (Pfizer), caspofungin [50, 67] . Temporal variations in resistance to echinocandins for the 5 most common Candida species are shown in Table 7 . Resistance to 1 or more of the echinocandins was distinctly uncommon among isolates of C. albicans (0.0%-0.1%), C. parapsilosis (0.0%-0.1%), C. tropicalis (0.5%-0.7%), and C. krusei (0.0%-1.7%). Resistance to anidulafungin (2.2%), caspofungin (3.5%), and micafungin (1.7%) was most prominent among C. glabrata isolates. No trend toward increasing resistance was seen over time for any of these species, although C. tropicalis exhibited an increase in resistance in 2015-2016 compared with previous years.
Previously, our investigators and others found echinocandin resistance in 8.0%-9.0% of fluconazole-resistant BSI isolates of C. glabrata [68] [69] [70] [71] [72] . In the SENTRY Program from 2006-2016, we noted co-resistance in fluconazole-resistant isolates of C. glabrata (5.5%-7.6%) and in fluconazole-resistant isolates of C. tropicalis (1.9%-3.6%) and C. krusei (0.0%-1.7%) as well (data not shown).
Emerging MDR strains of Candida spp. isolates are sure to complicate clinical decision-making at a time when few options exist for alternative antifungal therapy [4, 11, 73, 74] . Although the MDR phenotype is most often detected after prolonged exposure to both classes of agents [1, 6, 26, 65, 68, 70] , recent studies have demonstrated that under stress conditions, MSH2 DNA mismatch repair gene mutations may produce a hypermutable state and facilitate rapid acquisition of fluconazole, echinocandin, and amphotericin B resistance [71] . These findings may help to explain why echinocandin resistance in some studies has been associated with fluconazole exposure, although the drug targets and resistance mechanisms are distinctly different [1, 6, 26, [68] [69] [70] [71] [72] .
Micafungin Resistance by Geographic Area and by Species
Geographic trends in the resistance to micafungin for the 5 most common species of Candida are shown in Table 8 . Resistance was not detected among C. parapsilosis or C. krusei isolates from the 4 global geographic regions when using the current CLSI CBP values [38] . Resistance to micafungin (2.8%) was most prominent among C. glabrata isolates from NA, whereas none of the C. glabrata isolates from LATAM were resistant to micafungin (Table 8 ). Micafungin resistance rates were 0.1% for C. albicans isolates collected in NA and EUR, but all isolates of C. albicans from other regions were susceptible to this agent. Similarly, micafungin-resistant C. tropicalis isolates were only detected in NA (1.3% resistant) and LATAM (0.5% resistant). Previously, we examined the micafungin susceptibilities of BSI isolates of C. glabrata from US centers participating in the SENTRY Program and grouped the isolates by geographic area within the United States from 2001-2007 [54] and 2006-2011 [23] . In the present study, we build upon this experience and report the micafungin resistance for an additional 474 C. glabrata isolates collected from sentinel surveillance sites throughout the United States from 2014 through 2016 and stratify the results by US region (Table 9) [48] . As seen with fluconazole (Table  6 ), the frequency of micafungin resistance varied with patient age; the highest rate of resistance was observed in the 20-49-year age group (5.1%), and the lowest rate in the ≥70-year age group (0.5%) (data not shown). These findings of increasing echinocandin resistance among invasive isolates of C. glabrata throughout the United States are comparable to findings reported from a population-based candidemia survey conducted from 2008 to 2014 [26] . Whereas all HS mutations have been shown to influence the sensitivity of the GS enzyme complex to inhibition by the individual echinocandins, not all mutations will result in resistant or non-WT MIC values for all 3 echinocandins [75, 76] . For C. albicans, mutations at S641 and S645 are the most frequent and produce the most pronounced resistant phenotype [65, 76] . Previous reports indicated that C. glabrata isolates with the S663F mutation responded in vivo to high doses of either micafungin or caspofungin, but not to anidulafungin. In contrast, isolates with the S629P mutation failed to respond to even the highest dose of any of the 3 echinocandins [75] . Mutations at positions S663 and F659 in C. glabrata have been associated with breakthrough infections in patients receiving echinocandin therapy [68, 77, 78] , whereas patients infected with C. glabrata strains containing the I1379V and I634V mutations (susceptible to both anidulafungin and caspofungin) tend to respond to echinocandin therapy [68] . MIC distributions for the echinocandins and fluconazole for uncommon species of Candida (≥5 isolates) are shown in Table  11 . We included the antifungal susceptibility profiles of less common species, all identified by sequence-based or proteomic methods, to provide MIC information for these opportunistic pathogens that may still pose problems in selecting optimal therapy. Among the miscellaneous species of Candida, the emerging MDR C. auris strain has been called the "new kid on the block" in hospital-associated infections [79, 80] . (Table 11) . Isolates of C. dubliniensis, C. kefyr, and C. pelliculosa, as well as the azole-resistant species C. norvegensis and C. inconspicua, were all very susceptible to echinocandins (MIC 50/90 , ≤0.25 mg/L), although we detected single echinocandin-resistant strains of C. dubliniensis and C. kefyr, both of which harbored FKS mutations (Table 10) . 
Investigation of FKS Mutations in Echinocandin-
Activity of Antifungal Agents Tested Against Uncommon Species of
CONCLUSIONS
The SENTRY Antimicrobial Surveillance Program was designed to track antimicrobial resistance trends and the spectrum of microbial pathogens on a global scale. The SENTRY Antifungal Surveillance Program has unique features that distinguish it from other excellent surveillance programs, such as the PATH Alliance [24, 81, 82] , the ARTEMIS DISK study [53] , the SCOPE Program [83] , the NEMIS study [84] , and population-based surveillance conducted in the United States [44] , Australia [85] , Belgium [86] , Denmark [5] , Finland [87] , France [46, 88] , Norway [33] , Spain [89] , LATAM [90] , and Asia [91] . Whereas these programs are based in a single country, may track only nosocomial infections, and/or rely primarily on diverse susceptibility testing results from participating centers, the SENTRY Program monitors nosocomial and community-onset infections on a global scale and uses validated reference identification and susceptibility testing methods at a central monitoring laboratory and has done so for 20 years [7, 9, 29] .
Despite the low antifungal resistance rates among Candida isolates, continuously monitoring antifungal susceptibility patterns and understanding resistance mechanisms against antifungal agents seems to be a prudent endeavor. Reports of breakthrough infections [92] , increasing prevalence of uncommon species refractory to clinically available antifungal agents [93, 94] , and emerging resistance mechanisms [20, 68] highlight the importance of local and global surveillance studies. If the goals of surveillance programs are to identify emerging infectious threats, to monitor trends in antimicrobial resistance, and to contribute data that may be used by individual practitioners, institutions, and organizations developing drugs, then the combination of population-based and sentinel surveillance programs for IC has served its purpose to date [6, 7, 17] . The findings of the SENTRY Program (sentinel surveillance) support reports from population-based surveys conducted in the United States and other countries worldwide [6, 21, 22] . Specifically, the trend of increasing infections due to C. glabrata noted in the United States has also been observed in Australia and several European countries [6] . C. glabrata as a cause of IC accounted for 27.0% of all isolates in Australia and 35.0% in Denmark in 2015 [5, 85] as well as 27.3% in Belgium in 2014 [86] . The increase in C. glabrata infections in these countries has been linked to an increased use of azoles, to which C. glabrata is intrinsically less susceptible [5, 6, 57, 95, 96] . Similar to the SENTRY Program findings (Table 2) , C. parapsilosis and C. tropicalis were more prominent than C. glabrata in population-based surveys reported from India, LATAM, South Africa, and Asia [91, [97] [98] [99] [100] .
Likewise, trends in resistance to fluconazole documented in the SENTRY Program support observations reported from other sentinel and population-based surveys in the United States and other countries. Aside from intrinsically fluconazole-resistant species, such as C. krusei and C. auris, increasing rates of acquired resistance to fluconazole have been noted in other non-albicans species including C. glabrata, C. parapsilosis, and C. tropicalis. High rates of fluconazole-resistant C. glabrata have been reported from both the SENTRY Program and population-based surveillance conducted in the United States, Australia, Denmark, and Belgium [5, 6, 51, 85, 86] . Although fluconazole resistance is generally considered to be uncommon among C. parapsilosis isolates, SENTRY Program data from EUR and LATAM (Table  4) and reports from Brazil [101] , Finland [102] , and South Africa [99] suggest that fluconazole resistance in C. parapsilosis may emerge following drug pressure in the form of fluconazole treatment and prophylaxis, with subsequent patient-to-patient transmission within the hospital environment. C. tropicalis is generally susceptible to fluconazole [103] , and prophylaxis with this agent has been associated with a decrease in the incidence of C. tropicalis BSIs in US cancer treatment centers [104] . The SENTRY Program data highlight elevated resistance to fluconazole among isolates of C. tropicalis from the APAC region (Table 4) , supporting reports from Australia, Brazil, Taiwan, and Belgium documenting the emergence of fluconazole resistance in C. tropicalis clinical isolates [6, 85, 86] .
It is important to realize that there is not a single best way to conduct surveillance and provide useful information [31] . Whereas population-based surveillance efforts are unsurpassed in providing incidence data and risk factor profiles [5, 7, 44] , they are limited in time and space due to expense and labor-intensive designs. Sentinel surveillance programs designed to capture organisms and patient demographic data from representative sites spanning a larger geographical area and over a longer period of time serve to fill the gaps in time and space that are necessarily left by the more intensive and focused, yet intermittent, population-based programs [7, 111, 112] . Establishing the infrastructure necessary for conducting sentinel surveillance may facilitate more intensive surveillance in certain geographic areas, such as a single US state, and provide information that may approximate that obtained from a population-based program (eg, Emerging Infections and the Epidemiology of Iowa Organisms) [95, [113] [114] [115] .
In comparing these data, it is important to realize that the results of most surveillance studies have potential biases that reflect the population surveyed, the method for data collection, and the underlying purposes for data collection [31, 32, [108] [109] [110] 112 ]. Significant differences may exist regarding patterns of antimicrobial resistance and usage, and these differences are likely to affect the ability to compare data among different studies [31, 32, [109] [110] [111] . Thus, longitudinal surveillance (SENTRY Program) by the same methods and study sites is important in providing accurate estimates of trends in antibacterial and antifungal resistance [7, 9, 29, 34] .
In summary, we have provided a 20-year comparison of differences in species distribution and overall antifungal susceptibility profiles among IC-causing Candida isolates from 4 broad geographic regions (NA, LATAM, EUR, and APAC). The results document the sustained activities of fluconazole (azoles) and echinocandin antifungal agents against all IC isolates, except for MDR species such as C. glabrata, C. krusei, and C. auris. The differences in species distribution observed among the geographic areas may be due to several factors, but they most likely reflect variation in antifungal usage and infection control practices. The emergence of less common yet potentially MDR strains, such as C. auris, is a grave concern and argues in favor of continued global surveillance efforts to detect, characterize, and report emerging pathogenic species [73, 112, 113] .
